Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Mike Gart, Rhys Williams, Daniel Ermann

Blood (2025) 146 (Supplement 1): 6317.

https://doi.org/10.1182/blood-2025-6317

Published: 2025

Journal Articles

Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia

Brian Koffman, Xiaoliang Wang, Qianhong Fu, Dong Yuan, Derrick van Beuge, Gregory Maglinte, Erlene Seymour

Blood (2025) 146 (Supplement 1): 3894.

https://doi.org/10.1182/blood-2025-3894

Published: 2025

Journal Articles

Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL

Aryan Ayati, Xiaoliang Wang, Kanika Chandra, Qianhong Fu, Marjan Massoudi, Gregory Maglinte, Madhav Seshadri, Vivek Rudrapatna

Blood (2025) 146 (Supplement 1): 4528.

https://doi.org/10.1182/blood-2025-4528

Published: 2025

Journal Articles

Real-world treatment patterns and biomarker utilization among patients aged ≥65 years with CLL/SLL from 2020 to 2024

Paul Hampel, Daniel Ermann, Xiaoliang Wang, Peter Kardel, Caitlin Sheetz, Ashis Das, Qianhong Fu, Lee Ding, Gregory Maglinte, Erlene Seymour, Ryan Jacobs

Blood (2025) 146 (Supplement 1): 2723.

https://doi.org/10.1182/blood-2025-2723

Published: 2025

Journal Articles

Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study

Joanna Rhodes, Adam Kittai, Paul Hampel, Xiaoliang Wang, Qianhong Fu, Danni Zhao, Smriti Karwa, Olive Mbah, Ahmed Sawas, Benjamin Wagner, Rachel Myers, Derrick van Beuge, Gregory Maglinte, Erlene Seymour, Jacqueline Barrientos

Blood (2025) 146 (Supplement 1): 2720.

https://doi.org/10.1182/blood-2025-2720

Published: 2025

Journal Articles

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Jing-Zhou Hou, Rushir Choksi, Gregory Maglinte, Xiaoliang Wang, Anna Rui, Beverly Chigarira, Lindsay Aton, Melissa Hagan, Lisa Morere, Rhys Williams, Daniel Ermann

Blood (2025) 146 (Supplement 1): 8041.

https://doi.org/10.1182/blood-2025-8041

Published: 2025

Journal Articles

Incidence of cardiac-related deaths among patients aged ≥65 years with B-cell malignancies treated with ibrutinib

Ryan Jacobs, Alessandra Ferrajoli, Xiaoliang Wang, Qianhong Fu, Andrea Barthel, Neil Lamarre, Yajin Zhao, Jeffrey Anderson, Derrick van Beuge, Ayad K. Ali, Michael Fradley

Blood (2025) 146 (Supplement 1): 8066.

https://doi.org/10.1182/blood-2025-8066

Published: 2025

Journal Articles

Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL

Mengyang Di, Xiaoliang Wang, Qianhong Fu, Dong Yuan, Gregory Maglinte, Erlene Seymour, Joanna Rhodes

Blood (2025) 146 (Supplement 1): 6283.

https://doi.org/10.1182/blood-2025-6283

Published: 2025

Journal Articles

Real-world chronic lymphocytic leukemia/small lymphocytic lymphoma treatment patterns at Florida cancer specialists & research institute among patients receiving zanubrutinib immediately following prior BTKi therapy

Amanda Warner, Xiaoliang Wang, Ashley Hernandez, Christian Okitondo, Karen Carr, Gregory Maglinte, Judah Friedman

Blood (2025) 146 (Supplement 1): 8062.

https://doi.org/10.1182/blood-2025-8062

Published: 2025

Journal Articles

Real-world chronic lymphocytic leukemia (CLL)–specific biomarker testing patterns and frontline treatment patterns in patients with CLL/small lymphocytic lymphoma (SLL)

Timothy Reynolds, William Ye, Linda Chen, Archana Sagar, Mohammad Eskandari, Xiaoliang Wang, Lee Ding, Gregory Maglinte, Paul Godley

Blood (2025) 146 (Supplement 1): 8077.

https://doi.org/10.1182/blood-2025-8077

Published: 2025

Journal Articles

Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy

Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Gregory Calip, Mustafa S Ascha, Xiaoliang Wang, Samuel Rubinstein, Sascha A. Tuchman, Luciano J. Costa, Benjamin Haaland, Smith Giri, Hira S Mian, Rafael Fonseca, Douglas W. Sborov

Blood (2022) 140 (Supplement 1): 5223–5224.

https://doi.org/10.1182/blood-2022-165541

Published: 2022

Journal Articles

Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States

Natalia Neparidze, Krystal W. Lau, Xiaoliang Wang, Amy J. Davidoff, Scott F. Huntington, Omer Hassan Jamy, Gregory Calip, Harsh Shah, Deborah M. Stephens, Rebecca A. Miksad, Ravi Parikh, Samuel Takvorian, Gaurav Goyal, Erlene K Seymour

Blood (2021) 138 (Supplement 1): 1973.

https://doi.org/10.1182/blood-2021-153787

Published: 2021

Journal Articles

Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database

Gregory S Calip, Mustafa S Ascha, Xiaoliang Wang, Amy E Pierre, Kathleen Maignan, Niquelle B Wadé, Siyang Leng, Erlene K Seymour, Brian C-H Chiu, Karen Sweiss, Pritesh R Patel, Natalia Neparidze

Blood (2021) 138 (Supplement 1): 4121.

https://doi.org/10.1182/blood-2021-152774

Published: 2021

Journal Articles

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States

Gaurav Goyal, Krystal W. Lau, Xiaoliang Wang, Amy J. Davidoff, Scott F. Huntington, Omer Hassan Jamy, Gregory Calip, Harsh Shah, Deborah M. Stephens, Rebecca A. Miksad, Ravi Parikh, Samuel Takvorian, Natalia Neparidze, Erlene K Seymour

Blood (2021) 138 (Supplement 1): 1930.

https://doi.org/10.1182/blood-2021-153625

Published: 2021

Journal Articles

DDX41 Mutations in Myeloid Neoplasms and Acute Leukemias

Yang Zhang, MD, Fang Wang, MD, Xue Chen, MD, Hong Liu, MD, Xiaoliang Wang, MD, Jiaqi Chen, MD, Panxiang Cao, MS, Xiaoli Ma, MD, Hongxing Liu, MD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-143456

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia

Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia

Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL

Real-world treatment patterns and biomarker utilization among patients aged ≥65 years with CLL/SLL from 2020 to 2024

Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy

Incidence of cardiac-related deaths among patients aged ≥65 years with B-cell malignancies treated with ibrutinib

Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL

Real-world chronic lymphocytic leukemia/small lymphocytic lymphoma treatment patterns at Florida cancer specialists & research institute among patients receiving zanubrutinib immediately following prior BTKi therapy

Real-world chronic lymphocytic leukemia (CLL)–specific biomarker testing patterns and frontline treatment patterns in patients with CLL/small lymphocytic lymphoma (SLL)

Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy

Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States

Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States

DDX41 Mutations in Myeloid Neoplasms and Acute Leukemias

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only